Enter your terms above and click the 'Search' button.

Showing articles 0 to 10 of 10 Filter Applied: adverse drug reaction (Click to remove) Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis Neurol 102:e208006, Ng, HS.,et al, 2024 Acute acalculous cholecystitis Neurol 90:e1548-e1552, Croteau, D.,et al, 2018 Hemophagocytic Lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab Neurol 90:849-851, Saarela, M.,et al, 2018 Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis Neruol 90:852-854, Ferraro, D.,et al, 2018 Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis JAMA Neurol 73:757-759, Penkert, H.,et al, 2016 Acute Cholecystitis During Treatment with Alemtuzumab in 3 Patients with RRMS Neurol 87:2380-2381, Pfeuffer, S.,et al, 2016 Newer Agents in the Treatment of Multiple Sclerosis Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015 Alemtuzumab for Multiples Sclerosis: Who and When to treat? Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012 Monoclonal Antibody Therapies and Neurologic Disorders Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008 Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008 Showing articles 0 to 10 of 10